复旦张江股东王海波拟减持不超过10万股A股

Core Viewpoint - Fudan Zhangjiang Biopharmaceutical Co., Ltd. announced that shareholder Wang Haibo holds 51.8286 million shares, representing 5.00% of the total share capital, and plans to reduce his holdings due to personal funding needs [1] Group 1 - Wang Haibo's shares were acquired before the company's initial public offering and have been fully released from restrictions since June 19, 2023 [1] - Wang Haibo intends to reduce his holdings by no more than 100,000 shares within three months, which would account for up to 0.01% of the company's total share capital [1]